Advertisement

Immune Deficiency and Infection in Chronic Kidney Disease

  • Lei JiangEmail author
  • Ping Wen
Chapter

Abstract

Chronic kidney disease (CKD) has long been recognized to be associated with immune deficiency. CKD-associated immune deficiency is orchestrated by the innate immune system and adaptive immune system. Immune deficiency could lead to graft dysfunction and impaired response to vaccination. Owing to the immune deficiency of CKD patients, opportunistic infections such as fungal, Pneumocystis jiroveci, and virus are more common in patients with CKD than in the general population. The high mortality risk of patients with CKD has been partly attributed to the infected diseases. Interventions targeting the immune dysfunction and infection can improve the outcomes of CKD.

References

  1. 1.
    Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526–33.CrossRefGoogle Scholar
  2. 2.
    Sharif MR. Zahra Chitsazian, Mehdi Moosavian et al. immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015;9(2):84–96.PubMedGoogle Scholar
  3. 3.
    Cohen G, Hörl WH. Immune dysfunction in uremia—an update. Toxins. 2012;4(11):926–90.CrossRefGoogle Scholar
  4. 4.
    Vaziri ND, Pahl MV, Crum A, et al. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22(1):149–56.CrossRefGoogle Scholar
  5. 5.
    Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013;3(9):a015487.CrossRefGoogle Scholar
  6. 6.
    Buttqereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steriods. 2002;67(6):529–34.CrossRefGoogle Scholar
  7. 7.
    Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78:661–71.CrossRefGoogle Scholar
  8. 8.
    Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009;11(4):290–7.CrossRefGoogle Scholar
  9. 9.
    Shirani K, Hassani FV, Razavi-Azarkhiavi K, et al. Phytotrapy of cyclophosphamide-induced immunosuppression. Environ Toxicol Pharmacol. 2015;39(3):1262–75.CrossRefGoogle Scholar
  10. 10.
    Imiq JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013;3920:957–76.Google Scholar
  11. 11.
    Betjes MGH, Litjens NHR. Chronic kidney disease and premature ageing of the adaptive immune response. Curr Urol Rep. 2015;16:471.CrossRefGoogle Scholar
  12. 12.
    Kim JU, Kim M, Kim S, et al. Dendritic cell dysfunction in patients with end-stage renal disease. Immune Netw. 2017;17(3):152–62.CrossRefGoogle Scholar
  13. 13.
    Yoon JW, Gollapudi S, Pahl MV, et al. Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371–6.CrossRefGoogle Scholar
  14. 14.
    Khan A, El-Charabaty E, El-Sayegh S. Fungal infections in renal transplant patients. J Clin Med Res. 2015;7(6):371–8.CrossRefGoogle Scholar
  15. 15.
    Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.CrossRefGoogle Scholar
  16. 16.
    Singh NM, Husain S. AST infectious disease community of practice: aspergillosis in solid organ transplantation. Am J Transplant. 2013;13:228–41.CrossRefGoogle Scholar
  17. 17.
    Goto N, Futamura K, Okada M, et al. Management of Pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 10):81–90.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Gavalda J, Meije Y, Fortun J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):27–48.CrossRefGoogle Scholar
  19. 19.
    Whitle PL, Price JS, Backx M. Therapy and management of Pneumocystics jirovecii infection. J Funqi (Basel). 2018;4(4):E127.Google Scholar
  20. 20.
    Chapman JR, Marriott DJ, Chen SC, et al. Post-transplant Pneumocystis jirovecii pneumonia-are-emerged public health problem? Kidney Int. 2013;84(2):240–3.CrossRefGoogle Scholar
  21. 21.
    National Kidney Foundation KDOQI Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for vascular access. Am J Kidney Dis. 2006;48:S176–322.CrossRefGoogle Scholar
  22. 22.
    Clinical practice recommendations for peritoneal dialysis adequacy. Am J Kidney Dis. 2006;48(Suppl 1):S130–58.Google Scholar
  23. 23.
    Hemodialysis Adequacy Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48(Suppl 1):S2–90.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Centre for Kidney DiseaseSecond Affiliated Hospital, Nanjing Medical UniversityNanjingChina

Personalised recommendations